219 related articles for article (PubMed ID: 33529725)
21. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
23. Inflammation in cancer and depression: a starring role for the kynurenine pathway.
Sforzini L; Nettis MA; Mondelli V; Pariante CM
Psychopharmacology (Berl); 2019 Oct; 236(10):2997-3011. PubMed ID: 30806743
[TBL] [Abstract][Full Text] [Related]
24. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.
Godin-Ethier J; Hanafi LA; Piccirillo CA; Lapointe R
Clin Cancer Res; 2011 Nov; 17(22):6985-91. PubMed ID: 22068654
[TBL] [Abstract][Full Text] [Related]
25. IDO Targeting in Sarcoma: Biological and Clinical Implications.
Nafia I; Toulmonde M; Bortolotto D; Chaibi A; Bodet D; Rey C; Velasco V; Larmonier CB; Cerf L; Adam J; Le Loarer F; Savina A; Bessede A; Italiano A
Front Immunol; 2020; 11():274. PubMed ID: 32194552
[TBL] [Abstract][Full Text] [Related]
26. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.
Liu X; Newton RC; Friedman SM; Scherle PA
Curr Cancer Drug Targets; 2009 Dec; 9(8):938-52. PubMed ID: 20025603
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
28. The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma.
Sordillo PP; Sordillo LA; Helson L
Anticancer Res; 2017 May; 37(5):2159-2171. PubMed ID: 28476779
[TBL] [Abstract][Full Text] [Related]
29. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
Front Immunol; 2020; 11():55. PubMed ID: 32117235
[TBL] [Abstract][Full Text] [Related]
30. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry.
Nguyen TT; Shin DH; Sohoni S; Singh SK; Rivera-Molina Y; Jiang H; Fan X; Gumin J; Lang FF; Alvarez-Breckenridge C; Godoy-Vitorino F; Zhu L; Zheng WJ; Zhai L; Ladomersky E; Lauing KL; Alonso MM; Wainwright DA; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902132
[TBL] [Abstract][Full Text] [Related]
31. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
32. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
33. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
Onesti CE; Boemer F; Josse C; Leduc S; Bours V; Jerusalem G
J Transl Med; 2019 Jul; 17(1):239. PubMed ID: 31337401
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice.
Polyzos KA; Ovchinnikova O; Berg M; Baumgartner R; Agardh H; Pirault J; Gisterå A; Assinger A; Laguna-Fernandez A; Bäck M; Hansson GK; Ketelhuth DF
Cardiovasc Res; 2015 May; 106(2):295-302. PubMed ID: 25750192
[TBL] [Abstract][Full Text] [Related]
35. Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors.
Lancellotti S; Novarese L; De Cristofaro R
Curr Med Chem; 2011; 18(15):2205-14. PubMed ID: 21517759
[TBL] [Abstract][Full Text] [Related]
36. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
37. Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Davar D; Bahary N
Target Oncol; 2018 Apr; 13(2):125-140. PubMed ID: 29302770
[TBL] [Abstract][Full Text] [Related]
38. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
[TBL] [Abstract][Full Text] [Related]
39. Major Developments in the Design of Inhibitors along the Kynurenine Pathway.
Jacobs KR; Castellano-Gonzalez G; Guillemin GJ; Lovejoy DB
Curr Med Chem; 2017; 24(23):2471-2495. PubMed ID: 28464785
[TBL] [Abstract][Full Text] [Related]
40. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
